Poster Spotlight 1: Addressing Breast Cancer Disparities and Treatment Related Toxicities
Session Details
The text of the abstracts will be posted on Monday, November 24.
Moderator
Sonya A. Reid, Vanderbilt University Medical Center, Nashville, TN
Presentation numberPD1-01
Causes of diminished outcomes among rural breast cancer survivors
Michael T Halpern, University of Texas School of Public Health San Antonio, San Antonio, TX
Presentation numberPD1-02
Racial and Socioeconomic Disparities in Patterns of Metastatic Disease Presentation and Treatment Among Patients With de novo Metastatic HR-Positive, HER2-Negative Breast Cancer
Sarah Poland, The University of Chicago Medicine, Chicago, IL
Presentation numberPD1-03
The generalizability and transportability of FDA drug approvals in breast cancer from 2010 – 2025
Maya Nicole Birhiray, Indy Hematology Education, Indianapolis, IN
Presentation numberPD1-04
Early Outcomes from the IMPACCT Project (Improving Participation in Cancer Clinical Trials): An Intervention to Improve Clinical Trial Participation Among Underrepresented Cancer Patients.
Melissa Taylor, UCSF, San Francisco, CA
Presentation numberPD1-05
Real-world adoption, disparities and impact of neoadjuvant chemoimmunotherapy (NACT-IO) in early-stage, high-risk triple negative breast cancer (TNBC)
Inimfon Jackson, The University of Texas MD Anderson Cancer Center, Houston, TX
Presentation numberPD1-06
Racial/ethnic inequities in access to novel therapies and outcomes in triple negative breast cancer
Olive M. Mbah, Flatiron Health, New York, NY
Presentation numberPD1-07
Discussant: Breast Cancer Disparities
Electra Paskett, Ohio State University, Columbus, OH
Presentation numberPD1-08
Trade: 6-month abemaciclib tolerability after initial dose escalation in early HR+/HER2- breast cancer
Ilana Schlam, Dana Farber Cancer Institute, Boston, MA
Presentation numberPD1-09
Nausea as a Mediator of Olanzapine’s effect on Quality-of-Life Improvement in Patients Receiving Highly or Moderately Emetogenic Chemotherapy Insights from a Phase III NCORP RCT
Luke J Peppone, University of Rochester, Rochester, NY
Presentation numberPD1-10
Immune Age Acceleration as a Biomarker for Immune-Related Adverse Events in Early Triple-Negative Breast Cancer Treated with Perioperative Pembrolizumab
Ayelet Alpert, Rambam Health Care Campus, Haifa, Israel
Presentation numberPD1-11
Associations between the gut microbiome and aromatase inhibitor (AI)-associated musculoskeletal symptoms (AIMSS)
Aubrey Stickland, University of Michigan, Ann Arbor, MI
Presentation numberPD1-12
Discussant: Treatment Related Toxicities
Hope S. Rugo, UCSF Helen Diller Family Comprehensive Cancer Center, San Francisco, CA